期刊文献+

药物中间体5-溴-2-氯-N-环戊胺嘧啶-4-胺的有关物质含量分析方法

Determination of Drug Intermediate 5-bromo-2-chloro-N-cyclopentamine-pyrimidine-4-amine Related Substances Content
下载PDF
导出
摘要 建立了5-溴-2-氯-N-环戊胺嘧啶-4-胺高效液相色谱法测定有关物质含量的分析方法。以自身对照,按外标法加校正因子计算有关物质含量。使用Agilent HC-C18色谱柱,流动相为0.1%磷酸和乙腈,梯度洗脱;检测波长240 nm。各杂质在0.025~1.000μg/mL浓度范围内线性关系良好,平均加样回收率在90%~110%,其RSD小于5%。该方法快速、准确,适用于5-溴-2-氯-N-环戊胺嘧啶-4-胺有关物质含量分析方法的检测。 A high performance liquid chromatography method was established for the determination of 5-bromo-2-chloro-N-cyclopentamine-pyrimidine-4-amine related substances content.The content of the relevant substances according to the external standard method plus correction factor with self-comparison was calculated.A Agilent HC-C18 column was used with the mobile phase of 0.1%phosphoric acid and acetonitrile,gradient elution at the detection wavelength of 240 nm.It was linear for impurities in the range of 0.025~1.000μg/mL.The average recovery was between 90%to 110%,and RSD was less than 5%.The method was accurate,fast and suitable for the determination of 5-bromo-2-chloro-N-cyclopentamine-pyrimidine-4-amine related substances content.
作者 柳毅 张卫 王文标 高军龙 LIU Yi;ZHANG Wei;WANG Wen-biao;GAO Jun-long(Zhejiang Xianfeng Technology Co.,Ltd.,Zhejiang Linhai 317021,China)
出处 《广州化工》 CAS 2023年第21期85-87,共3页 GuangZhou Chemical Industry
关键词 5-溴-2-氯-N-环戊胺嘧啶-4-胺 高效液相色谱 自身对照 校正因子 5-bromo-2-chloro-N-cyclopentamine-pyrimidine-4-amine HPLC self-comparison correction factor
  • 相关文献

参考文献4

二级参考文献24

  • 1Baselga J, Campone M, Piccart M, et al.Everolimus in postmenopausalhormone-receptor-positive advanced breast cancer[J].N Engl J Med,2012, 366(6): 520-529.
  • 2Akinleye A, Avvaru P, Furqan M, et al.Phosphatidylinositol 3-kinase(PI3K)inhibitors as cancer therapeutics[J]J Hematol Oncol, 2013, 6(1): 88.
  • 3Takalkar A,Adams S,Subbiah V.Radium-223 dichloride bone-targetedalpha particle therapy for hormone-refractory breast cancer metastatic tobone[J].Experimental Hematol Oncol, 2014,3(1): 1-7.
  • 4Verma S, Miles D, Gianni L, et al.Trastuzumab emtansine for HER2-positive advanced breast cancer[J].N Engl J Med, 2012,367(19): 1783-1791..
  • 5Incorvati J A, Shah S, Mu Y, et al.Targeted therapy for HER2 positivebreast cancer[J].J Hematol Oncol, 2013, 6(23): 1-9.
  • 6Akinleye A,Chen Y, Mukhi N, et al.Ibrutinib and novel BTK inhibitorsin clinical development[J].J Hematol Oncol, 2013, 6(1): 59.
  • 7Finn R, Dering J,Conklin D, et al.PD 0332991,a selective cyclin Dkinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogenreceptor-positive human breast cancer cell lines in vitro[J].Breast CancerRes, 2009, 11(5): R77.
  • 8Finn R S, Crown J P, Lang I,et al.The cyclin-dependent kinase 4/6inhibitor palbociclib in combination with letrozole versus letrozole aloneas first-line treatment of oestrogen receptor-positive,HER2-negative,advanced breast cancer (PALOMA- 1/TRIO-18) : a randomised phase 2study[J]丄ancet Oncol, 2015, 16(1): 25-35.
  • 9Turner N C, Ro J, Andre F, et al.Palbociclib in hormone-receptor-positive advanced breast cancer[J].The New England Journal of Medicine,2015,373(3): 209-219.
  • 10Kim S, Loo A, Chopra R* et al.Abstract PR02 : LEE011 : an orallybioavailable, selective small molecule inhibitor of CDK4/6 - reactivatingRb in cancer[J].Mol Cancer Ther, 2013,12(11 Supplement): R02.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部